Latest from Rutgers Cancer Institute of New Jersey

Investigators found no statistically significant difference in survival between radical prostatectomy alone and external beam radiotherapy plus brachytherapy with or without ADT after adjusting for imbalances in prostate cancer prognostic factors.

Mark Stein, MD, medical oncologist, Rutgers Cancer Institute of New Jersey, discusses androgen receptor–resistance in prostate cancer.

Mark Stein, MD, medical oncologist, Rutgers Cancer Institute of New Jersey, discusses trials investigating the use of circulating tumor cells as biomarkers for patients with prostate cancer.

Biomarkers play a key role in the optimization of treatments for patients with prostate cancer. According to Mark Stein, MD, they can even serve as clinical endpoints in trials.

Mark Stein, MD, medical oncologist, Rutgers Cancer Institute of New Jersey, discusses the use of novel circulating biomarkers in the treatment of patients with prostate cancer.

?Janice Mehnert, MD, medical oncologist, director, Phase I and Developmental Therapeutics Program, Rutgers Cancer Institute of New Jersey, discusses challenges with identifying effective biomarkers in for immunotherapy agents.

Rutgers Cancer Institute of New Jersey to train the next generation of cancer researchers.

Howard L. Kaufman, MD, FACS, Chief Surgical Officer, Associate Director for Clinical Science, Surgical Oncologist, Rutgers Cancer Institute, Society for Immunotherapy of Cancer (SITC) President, discusses the impact of the recent FDA approval of talimogene laherparepvec (T-VEC) for the treatment of melanoma lesions in the skin and lymph nodes.